

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report: July 19, 2016
(Date of earliest event reported: July 18, 2016)

Revlon, Inc.
(Exact Name of Registrant as Specified in its Charter)

Delaware	1-11178	13-3662955
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer No.)

One New York Plaza, New York, New York	10004
(Address of Principal Executive Offices)	(Zip Code)

(212) 527-4000
(Registrant's telephone number, including area code)

None
(Former Name or Former Address, if Changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 2.02 Results of Operations and Financial Condition.

Revlon, Inc. (“Revlon”), in connection with the pending acquisition (the “Acquisition”) of Elizabeth Arden, Inc. (together with its subsidiaries, “Elizabeth Arden”) by Revlon’s wholly owned subsidiary Revlon Consumer Products Corporation (“RCPC” and, together with Revlon, the “Company”) and certain related refinancing transactions (together with the Acquisition, the “Transactions”), as previously disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on June 17, 2016, issued a press release on July 18, 2016 announcing certain preliminary unaudited financial results for Revlon’s second fiscal quarter ended June 30, 2016. The complete release is attached to this report as Exhibit 99.1 and is incorporated by reference herein in its entirety.

In connection with the Transactions, the Company provided to potential investors the unaudited pro forma condensed combined financial information of RCPC giving effect to the Transactions on a pro forma basis. Such pro forma condensed combined financial information is attached to this report as Exhibit 99.2 and is incorporated by reference herein in its entirety. The unaudited pro forma condensed combined statements of operations combine the historical consolidated statements of operations of RCPC and Elizabeth Arden, giving effect to the Transactions as if they had been completed on January 1, 2015. The unaudited pro forma condensed combined balance sheet combines the historical consolidated balance sheets of RCPC and Elizabeth Arden, giving effect to the Transactions as if they had occurred on March 31, 2016. Neither the pro forma financial information of RCPC nor the historical financial statements of RCPC and Elizabeth Arden represent financial information of Revlon. The pro forma financial information presented in Exhibit 99.2 is unaudited and is provided for informational purposes only, and it does not constitute Revlon’s pro forma condensed combined financial information related to the Acquisition, with respect to which Revlon will file a Form 8-K containing such information with the SEC within the time required by Item 9.01 of Form 8-K.

The Company additionally provided to potential investors, in connection with the Transactions, certain non-GAAP financial information which management believes provides useful information to potential investors. Reconciliations of these non-GAAP financial measures to their most directly comparable financial measures calculated and presented in accordance with U.S. GAAP are attached to this report as Exhibit 99.2 and are incorporated by reference herein in their entirety.

In accordance with General Instruction B.2 to the Form 8-K, the information under this Item 2.02 shall be deemed to be “furnished” to the SEC and not be deemed to be “filed” with the SEC for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

Forward-Looking Statements

Statements and other information included in this Current Report on Form 8-K, which are not historical facts, including statements about the Company’s plans, projected financial results and liquidity, strategies, expected synergies, focus, beliefs and expectations, as well as certain assumptions used by the Company’s management, are forward-looking and subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date they are made and, except for the Company’s ongoing obligations under the U.S. federal securities laws, the Company undertakes no obligation to publicly update any forward-looking statement, whether to reflect actual results of operations; changes in financial condition; changes in general U.S. or international economic, industry or cosmetics category conditions; changes in estimates, expectations or assumptions, including with respect to results of operations and liquidity; or other circumstances, conditions, developments or events arising after the filing of this Current Report on Form 8-K. Such forward-looking statements include, without limitation, the Company’s beliefs, expectations, guidance, focus and/or plans regarding future events, including the Company’s plans to consummate the Acquisition and the related financing transactions, as well as the terms and conditions and timing of such transactions.

Forward-looking statements are subject to known and unknown risks and uncertainties and are based on preliminary or potentially inaccurate estimates and assumptions, including the estimates and assumptions used by the Company in preparing the pro forma financial information referenced in this Current Report on Form 8-K, that could cause actual results to differ materially from those expected or implied by the pro forma financial information or the estimates and assumptions used in preparing the pro forma financial information. Actual results also may differ materially from such forward-looking statements for a number of other reasons, including as a result of the risks described in other items in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC during 2016 (which may be viewed on the SEC's website at <http://www.sec.gov> or on Revlon's website at <http://www.revloninc.com>). Additional important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the Acquisition not being timely completed, if completed at all; risks associated with the financing of the transaction; prior to the completion of the Acquisition, the Company's or Elizabeth Arden's respective businesses experiencing disruptions due to transaction-related uncertainty or other factors making it more difficult to maintain relationships with employees, business partners or governmental entities; and the parties being unable to successfully implement integration strategies or realize the anticipated benefits of the Acquisition, including the possibility that the expected synergies and cost reductions from the Acquisition will not be realized or will not be realized within the expected time period. Factors other than those referred to above could also cause the Company's results to differ materially from expected results. Additionally, the business and financial materials and any other statement or disclosure on, or made available through, the Company's websites or other websites referenced herein shall not be incorporated by reference into this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release dated July 18, 2016
99.2	Financial Information of the Company

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REVLON, INC.

By: /s/ Michael T. Sheehan

Michael T. Sheehan

Senior Vice President, Deputy General Counsel and Secretary

Date: July 19, 2016

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release dated July 18, 2016
99.2	Financial Information of the Company

REVLON REPORTS PRELIMINARY SECOND QUARTER 2016 RESULTS

New York, New York (July 18, 2016) -- Revlon, Inc. (NYSE: REV) announced today preliminary unaudited financial results for its second quarter ended June 30, 2016. These preliminary results are being provided in connection with the Company's previously disclosed financing efforts that will provide the funds to consummate the acquisition of Elizabeth Arden, Inc., which was announced on June 16, 2016.

Preliminary results for the second quarter 2016 include:

- Net sales of approximately \$489 million, compared to net sales of \$482 million in the prior year quarter, a growth of 1.3%, or 3.5% excluding the impact of foreign currency ("XFX").
- Adjusted EBITDA of approximately \$89 million, compared to Adjusted EBITDA of approximately \$90 million in the second quarter of 2015, a decline of 1.1%, or flat XFX.
- As Reported Operating income of approximately \$52 million, compared to approximately \$61 million in the second quarter of 2015.

Preliminary results for the first six months of 2016 include:

- Net sales of approximately \$929 million, compared to net sales of approximately \$921 million for the first six months of 2015, a growth of 0.8%, or 3.5% XFX.
- Adjusted EBITDA of approximately \$157 million, compared to Adjusted EBITDA of approximately \$161 million for the first six months of 2015, a decline of 3%, or 2.0% XFX.
- As Reported Operating income of approximately \$88 million, compared to approximately \$106 million for the first six months of 2015.

Commenting on the second quarter of 2016 preliminary results, Revlon's President and Chief Executive Officer, Fabian Garcia, said "I am delighted with our continued trajectory of net sales growth in the second quarter. Once again, growth was fueled by product innovation and strong performance by established brands in both the Consumer and Professional segments. Our most salient innovations in our Consumer segment included the new Revlon Mascara collection, Ultra HD Matte lipcolor and the Kylie SinfulShine Collection. Mitchum anti-perspirant deodorants and Cutex nail products also performed well. In our Professional segment, American Crew's line of special edition grooming products honoring Elvis Presley, an ultimate style icon, has continued to demonstrate strong sales in salons, as have Revlon Professional hair products." Mr. Garcia continued "During the second quarter of 2016 we also announced that Revlon signed an agreement to acquire Elizabeth Arden, Inc. and we are very excited about the strategic long-term growth platform that this acquisition will provide for us to enter into new categories, channels and markets. We expect to close this acquisition by the end of 2016, subject to customary closing conditions."

Preliminary net sales in the second quarter of 2016 grew 3.5% XFX, driven by higher net sales in our Consumer segment throughout most of the international region. From a brand perspective, Consumer segment net sales growth was driven by higher net sales of Revlon color cosmetics, Cutex nail products, SinfulColors color cosmetics and Mitchum anti-perspirant deodorants, partially offset by lower net sales of Almay color cosmetics. Professional segment net sales were essentially flat in the second quarter of 2016, compared to the second quarter of 2015, primarily due to higher net sales of Revlon Professional hair products and American Crew men's grooming products throughout the international region, mostly offset by lower net sales of CND nail products due to the timing of product launches.

Preliminary Adjusted EBITDA was essentially flat, XFX, in the second quarter of 2016, compared to the second quarter of 2015, driven by the increase in net sales in the second quarter of 2016, offset by higher cost of goods as a result of product and country mix, as well as the unfavorable impact from transaction FX.

This release presents the Company's preliminary second quarter 2016 results using both U.S. GAAP ("As Reported") and non-GAAP ("Adjusted") measures. Adjusted measures exclude certain non-operating items from As Reported results and other unusual items identified by management that impact the comparability of the Company's period-over-period preliminary results. As a result of the exclusion of these unusual items, the definition of Adjusted EBITDA has changed from that used in prior periods, and Adjusted EBITDA for prior periods presented in this release will be different from amounts reported in prior periods. In addition, the preliminary results have not been audited or reviewed by the Company's independent registered public accounting firm and are subject to further adjustment. See footnote (a) for further discussion of the Company's Adjusted preliminary measures. Reconciliations of As Reported results to Adjusted results are provided as an attachment to this press release.

Preliminary Financial Information. The preliminary financial information set forth in this press release has been prepared by the Company's management. The foregoing information and estimates are unaudited and have not been compiled, reviewed or examined by the Company's independent registered public accounting firm, nor have the Company's independent registered public accounting firm performed any procedures with respect to this information or expressed any opinion or any form of assurance on such information. In addition, the foregoing information and estimates are subject to revision as the Company prepares its consolidated financial statements and other disclosures as of and for the three and six months ended June 30, 2016, including all disclosures required by U.S. GAAP and pursuant to SEC rules and regulations. Because the Company has not completed its normal quarterly closing and review procedures for the three and six months ended June 30, 2016, and subsequent events may occur that require material adjustments to these results, the final results and other disclosures for the three and six months ended June 30, 2016 may differ materially from these preliminary estimates. These preliminary estimates should not be viewed as a substitute for full financial statements prepared in accordance with U.S. GAAP or as a measure of the Company's performance. See "Forward-Looking Statements."

Second Quarter 2016 Results Conference Call

The Company will host a conference call with members of the investment community on July 29, 2016 at 9:30 A.M. EDT to discuss second quarter 2016 results. Access to the call is available to the public at www.revloninc.com.

Investor Relations:

Siobhan Anderson 212-527-4656

or

Media Relations:

Pamela Alabaster 212-527-5863

Footnotes to Press Release

(a) **Non-GAAP Financial Measures:** EBITDA and Adjusted EBITDA are non-GAAP financial measures that are reconciled to their most directly comparable GAAP measures in the accompanying financial tables. With respect to Adjusted EBITDA for the second quarter and first six months of 2016, we are providing a quantitative reconciliation to the most directly comparable GAAP measure, operating income. We cannot provide a reconciliation to net income without unreasonable effort, as, among other things, certain items that impact these measures, such as adjustments to the provision for income taxes, have not yet been finalized.

The Company defines EBITDA as income from continuing operations before interest, taxes, depreciation, amortization, gains/losses on foreign currency fluctuations, gains/losses on the early extinguishment of debt, and miscellaneous expenses (the foregoing being the “EBITDA Exclusions”). To reflect the impact of non-cash stock compensation expense and certain other non-operating items that are not directly attributable to the Company’s underlying operating performance (the “Non-Operating Items”), the Company presents Adjusted EBITDA to exclude these Non-Operating Items and to exclude the impact of certain unusual items impacting the comparability of the Company’s period-over-period results as seen through the eyes of management (the “Unusual Items”). The following table identifies the Non-Operating and Unusual Items excluded in the presentation of Adjusted EBITDA for all periods:

(USD millions) Income / (Loss) Adjustments to EBITDA	Q2 2016	Q2 2015
Non-Operating Items:		
Non-cash stock compensation expense	\$ (1)	\$ (1)
Restructuring and related charges	(1)	3
Acquisition and integration costs	(6)	(5)
Deferred Consideration for CBB Acquisition	(1)	(1)
Inventory Purchase Accounting Adjustment	(0)	(1)
Unusual Items:		
Gain on sale of certain non-core professional brands	\$ —	\$ —
Executive Management Changes	(2)	—

(USD millions) Income / (Loss) Adjustments to EBITDA	YTD 2016	YTD 2015
Non-Operating Items:		
Non-cash stock compensation expense	\$ (3)	\$ (3)
Restructuring and related charges	(2)	2
Acquisition and integration costs	(6)	(6)
Deferred Consideration for CBB Acquisition	(2)	(1)
Inventory Purchase Accounting Adjustment	(0)	(1)
Unusual Items:		
Gain on sale of certain non-core professional brands	\$ —	\$ 3
Executive Management Changes	(3)	—

The Company excludes the EBITDA Exclusions, Non-Operating Items and Unusual Items, as applicable, in calculating non-GAAP measures because the Company’s management believes that some of these items may not occur in certain periods, the amounts recognized can vary significantly from period to period and these items do not facilitate an understanding of the Company’s underlying operating performance.

The Company's management uses EBITDA and Adjusted EBITDA as operating performance measures (in conjunction with GAAP measures), as an integral part of its reporting and planning processes and to, among other things: (i) monitor and evaluate the performance of the Company's business operations, financial performance and overall liquidity; (ii) facilitate management's internal comparisons of the Company's historical operating performance of its business operations; (iii) facilitate management's external comparisons of the results of its overall business to the historical operating performance of other companies that may have different capital structures and debt levels; (iv) review and assess the operating performance of the Company's management team and, together with other operational objectives, as a measure in evaluating employee compensation and bonuses; (v) analyze and evaluate financial and strategic planning decisions regarding future operating investments; and (vi) plan for and prepare future annual operating budgets and determine appropriate levels of operating investments.

Management believes that EBITDA and Adjusted EBITDA are useful to investors to provide them with disclosures of the Company's operating results on the same basis as that used by management. Additionally, management believes that EBITDA and Adjusted EBITDA provide useful information to investors about the performance of the Company's overall business because such measures eliminate the effects of unusual or other infrequent charges that are not directly attributable to the Company's underlying operating performance. Additionally, management believes that providing these non-GAAP measures enhances the comparability for investors in assessing the Company's financial reporting.

Accordingly, the Company believes that the presentation of EBITDA and Adjusted EBITDA, when used in conjunction with GAAP financial measures, are useful financial analytical measures, that are used by management, as described above and therefore can assist investors in assessing the Company's financial condition, operating performance and underlying strength. EBITDA and Adjusted EBITDA should not be considered in isolation or as a substitute for their respective most directly comparable As Reported measures prepared in accordance with GAAP, such as operating income. Other companies may define such non-GAAP measures differently. Also, while EBITDA is defined differently than Adjusted EBITDA for the Company's credit agreements and indenture, certain financial covenants in its borrowing arrangements are tied to similar measures. These non-GAAP financial measures should be read in conjunction with the Company's financial statements and related footnotes filed with the SEC.

Forward-Looking Statements

Statements made in this press release, which are not historical facts, are forward-looking and subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date they are made and, except for the Company's ongoing obligations under the U.S. federal securities laws, the Company undertakes no obligation to publicly update any forward-looking statement, whether to reflect actual results of operations; changes in financial condition; changes in general U.S. or international economic or industry conditions and/or conditions in the Company's reportable segments; changes in estimates, expectations or assumptions; or other circumstances, conditions, developments or events arising after the issuance of this press release. Such forward-looking statements include, without limitation: (i) the Company's ongoing quarterly closing and review process with respect to its quarter ended June 30, 2016, (ii) the review process by the Company's independent registered public accounting firm with respect to the consolidated financial statements and other disclosures as of and for the three and six months ended June 30, 2016; (iii) the Company's excitement about the strategic long-term growth platform that the Elizabeth Arden, Inc. acquisition will provide for us to enter into new categories, channels and markets; and (iv) the Company's expectation to close the Elizabeth Arden acquisition by the end of 2016, subject to customary closing conditions. Actual results may differ materially from such forward-looking statements for a number of reasons, including as a result of the risks described and other items in Revlon's or Elizabeth Arden's filings with the SEC, including in Revlon's and Elizabeth Arden's respective Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC during 2016 (which may be viewed on the SEC's website at <http://www.sec.gov> or on Revlon, Inc.'s website at <http://www.revloninc.com> or on Elizabeth Arden's website at <http://corporate.elizabetharden.com>, as applicable). Additional important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: (i) the acquisition not being timely completed, if completed at all; (ii) risks associated with the financing of the transaction; (iii) prior to the completion of the acquisition, Revlon's or the Elizabeth Arden's respective businesses experiencing disruptions due to transaction-related uncertainty or other factors making it more difficult to maintain relationships with employees, business partners or governmental entities; and/or (iv) the parties being unable to successfully implement integration strategies or realize the anticipated benefits of the acquisition, including the possibility that the expected synergies and cost reductions from the proposed acquisition will not be realized or will not be realized within the expected time period, such as due to, among other things, unanticipated circumstances, trends or events affecting the Company's financial performance, including decreased consumer spending in response to weak economic conditions or weakness in the consumption of beauty-related products; lower than expected acceptance of new products; adverse changes in foreign currency exchange rates; decreased sales of products as a result of increased competitive activities by competitors; and/or decreased performance by third party suppliers. Factors other than those referred to above could also cause Revlon's or Elizabeth Arden's results to differ materially from expected results. Additionally, the business and financial materials and any other statement or disclosure on, or made available through, Revlon's or Elizabeth Arden's websites or other websites referenced herein shall not be incorporated by reference into this press release.

REVLON, INC. AND SUBSIDIARIES
EBITDA AND ADJUSTED EBITDA RECONCILIATION
(dollars in millions)

	Three Months Ended June 30,	
	2016	2015
(Unaudited)		
Reconciliation to operating income:		
Operating Income	\$ 52	\$ 61
Depreciation and amortization	26	25
EBITDA	79	86
Non-operating items:		
Non-cash stock compensation expense	1	1
Restructuring and related charges	1	(3)
Acquisition and integration costs	6	5
Inventory purchase accounting adjustment	0	1
Deferred consideration for CBB acquisition	1	1
Unusual items:		
Executive management changes	2	—
Adjusted EBITDA	<u>\$ 89</u>	<u>\$ 90</u>

* Schedule may not foot due to rounding

	Six Months Ended June 30,	
	2016	2015
(Unaudited)		
Reconciliation to operating income:		
Operating Income	\$ 88	\$ 106
Depreciation and amortization	52	51
EBITDA	140	157
Non-operating items:		
Non-cash stock compensation expense	3	3
Restructuring and related charges	2	(2)
Acquisition and integration costs	6	6
Inventory purchase accounting adjustment	0	1
Deferred consideration for CBB acquisition	2	1
Unusual items:		
Gain on sale of certain non-core professional brands	—	(3)
Executive management changes	3	—
Adjusted EBITDA	<u>\$ 157</u>	<u>\$ 161</u>

* Schedule may not foot due to rounding

OVERVIEW

On June 16, 2016, Revlon, Inc., a Delaware corporation (“Parent”), Revlon Consumer Products Corporation, a Delaware corporation and wholly owned subsidiary of Parent (“Products Corporation”) and RR Transaction Corp., a Florida corporation and wholly owned subsidiary of Products Corporation (“Acquisition Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Elizabeth Arden, Inc., a Florida corporation (together with its subsidiaries, “Elizabeth Arden”) pursuant to which Acquisition Sub will merge with and into Elizabeth Arden, Inc. with Elizabeth Arden, Inc. surviving as a wholly owned subsidiary of Products Corporation (the “Acquisition”). The information set forth in this Exhibit 99.2 was provided to prospective investors in connection with the Acquisition.

In connection with the Acquisition, Products Corporation expects to enter into a seven-year \$1,800.0 million senior secured term loan facility (the “New Term Loan Facility”) and a five-year \$400.0 million senior secured asset-based revolving credit facility (the “New Revolving Credit Facility” and, together with the New Term Loan Facility, the “New Senior Facilities”) and \$400.0 million of senior unsecured financing (the “New Unsecured Financing”). Products Corporation intends to use the proceeds of the New Unsecured Financing and the New Term Loan Facility, together with approximately \$100.0 million of borrowings under the New Revolving Credit Facility and approximately \$17.9 million of cash on hand (subject in each case to changes in working capital requirements and other adjustments), to fund the purchase price of the Acquisition and to also repay, refinance or retire (amounts outstanding as of March 31, 2016):

- (i) \$1,311.7 million aggregate principal amount of Products Corporation’s existing (a) 2011 term loan due 2017; and (b) 2013 term loan due 2019, which are governed by the same term loan facility agreement (collectively, the “Existing Term Loan”);
- (ii) \$350.0 million aggregate principal amount of Elizabeth Arden, Inc.’s 7³/₈% senior notes due 2021 (the “Existing Elizabeth Arden Notes”);
- (iii) \$42.5 million aggregate principal amount of borrowings under Elizabeth Arden, Inc.’s \$300.0 million revolving credit facility (the “Elizabeth Arden Revolving Facility”);
- (iv) \$25.0 million aggregate principal amount of borrowings under Elizabeth Arden, Inc.’s second lien credit facility (the “Elizabeth Arden Second Lien Facility”); and
- (v) \$55.0 million liquidation preference of Elizabeth Arden, Inc.’s Series A Serial Preferred Stock, par value \$0.01 per share (the “Elizabeth Arden Preferred Stock”).

In addition, Products Corporation expects to terminate its existing \$175.0 million amended revolving credit facility due 2018 (the “Existing Revolver” and, together with the Existing Term Loan, the “Existing Senior Facilities”).

The Company also expects to pay Acquisition-related costs of \$30.4 million, as discussed in Note 4(d) below, which would be paid using cash on hand.

The Existing Term Loan and, collectively with the Existing Elizabeth Arden Notes, Elizabeth Arden Revolving Facility, the Elizabeth Arden Second Lien Facility and the Elizabeth Arden Preferred Stock are referred to as the “Refinanced Indebtedness.” The entry into the New Senior Facilities and New Unsecured Financing, the repayment of the Refinanced Indebtedness, plus accrued and unpaid interest and dividends thereon and the termination of the Existing Revolver are collectively referred to herein as the “Refinancing Transactions”; and the Acquisition, together with the Refinancing Transactions, are referred to herein as the “Transactions.”

As used herein, unless otherwise indicated or the context otherwise requires, the “Company,” “we,” “us,” and “our” (and words of similar import) refer to (i) prior to the completion of the Transactions, Products Corporation and its consolidated subsidiaries, and (ii) after the completion of the Transactions and giving pro forma effect to the Transactions, Products Corporation and its consolidated subsidiaries (including Elizabeth Arden, Inc. and its consolidated subsidiaries). References to “MacAndrews & Forbes” refer to MacAndrews & Forbes Incorporated, together with certain of its affiliates other than the Company.

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

The unaudited pro forma condensed consolidated financial information set forth below was provided to potential investors by Products Corporation in connection with the Acquisition.

The following unaudited pro forma condensed combined balance sheet combines our unaudited historical consolidated balance sheet as of March 31, 2016 with the unaudited historical consolidated balance sheet of Elizabeth Arden as of March 31, 2016, giving effect to the Transactions (as defined below) on a pro forma basis as if they had been completed on March 31, 2016. The unaudited pro forma condensed combined statements of operations for the three months ended March 31, 2016 and 2015, and the fiscal year ended December 31, 2015 combines our unaudited historical consolidated statements of operations for the periods then ended with the unaudited historical consolidated statements of operations of Elizabeth Arden for the three months ended March 31, 2016 and 2015 and the calculated fiscal year ended December 31, 2015 (as discussed below), and gives effect to the Transactions on a pro forma basis as if they had been completed on January 1, 2015. The unaudited pro forma condensed combined financial statements show the impact of the Transactions on our and Elizabeth Arden's respective historical consolidated financial positions and results of operations under the acquisition method of accounting, in accordance with ASC Topic 805, "Business Combinations," with Products Corporation treated as the acquiror of Elizabeth Arden.

The unaudited pro forma condensed combined financial statements reflect certain adjustments to Elizabeth Arden's historical consolidated financial statements to align those financials with our U.S. GAAP accounting policies. These adjustments reflect our best estimates based upon the information currently available to us. Additionally, certain items have been reclassified from Elizabeth Arden's historical unaudited consolidated financial statements to align the presentation of those financial statements with our financial statement presentation. These reclassifications were determined based upon the information currently available to us, and additional reclassifications may be necessary once the acquisition accounting is completed and additional information becomes available to us.

The Transactions will be accounted for under the acquisition method of accounting, whereby the assets acquired and liabilities assumed will be measured at their respective fair values as of the date of completion of the Acquisition, with any residual value reflected as goodwill. The determination of the fair values of the net assets acquired, including intangible and net tangible assets, is based upon certain valuations that have not been finalized, and, accordingly, the adjustments to record the assets acquired and liabilities assumed at fair value reflect our best estimates and are subject to change once further analyses are completed. Under applicable guidance, we are not required to finalize our acquisition accounting until one year after the Acquisition is completed, and any subsequent adjustments made in connection with the finalization of our acquisition accounting may be material.

The unaudited pro forma condensed combined statements of operations do not include: (1) any revenue or cost reduction synergies that may be achieved subsequent to the completion of the Transactions; or (2) the impact of non-recurring items directly related to the Transactions.

The pro forma condensed combined financial statements are unaudited, are presented for informational purposes only, and are not necessarily indicative of the financial position or results of operations that would have occurred had the Transactions been completed as of the dates or at the beginning of the periods presented. In addition, the unaudited pro forma condensed combined financial statements do not purport to project the future consolidated financial position or operating results of the combined companies. The unaudited pro forma condensed combined financial statements and the accompanying notes should be read together with:

- the separate audited historical consolidated financial statements of Products Corporation for the year ended December 31, 2015;
- the separate audited historical consolidated financial statements of Elizabeth Arden for the fiscal year ended June 30, 2015;
- the separate unaudited historical consolidated financial statements of Products Corporation as of and for the three months ended March 31, 2016;
- the separate unaudited condensed historical consolidated financial statements of Elizabeth Arden as of and for the three and nine months ended March 31, 2016;
- the separate unaudited condensed historical consolidated financial statements of Elizabeth Arden as of and for the three and six months ended December 31, 2015;

- the separate unaudited condensed historical consolidated financial statements of Elizabeth Arden as of and for the three and six months ended December 31, 2014;
- the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the periodic reports of Products Corporation containing the financial information of Products Corporation listed above; and
- the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the periodic reports of Elizabeth Arden containing the financial information of Elizabeth Arden listed above.

The foregoing financial and other information may be found in the periodic filings of Products Corporation and Elizabeth Arden, which have been filed with the Securities and Exchange Commission.

The unaudited pro forma condensed combined statements of operations have been presented based our fiscal year, which ends on December 31. The following historical statement of operations data of Elizabeth Arden have been arithmetically combined for the purposes of the preparation of the unaudited pro forma condensed combined statement of operations for the twelve months ended December 31, 2015 but have not been audited or reviewed by any firm of independent registered public accountants:

- the separate audited historical consolidated statement of operations data of Elizabeth Arden for the fiscal year ended June 30, 2015; plus
- the separate unaudited historical consolidated statement of operations data of Elizabeth Arden for the six months ended December 31, 2015; minus
- the separate unaudited historical consolidated statement of operations data of Elizabeth Arden for the six months ended December 31, 2014.

Because Elizabeth Arden’s statement of operations data for the twelve months ended December 31, 2015 represent an arithmetic combination of the data for the above-described fiscal periods and because the twelve months ended December 31, 2015 are not a fiscal period of Elizabeth Arden, such data may not be comparable to or indicative of the results of operations of Elizabeth Arden for a full fiscal year. In addition, because such statement of operations data have not been audited or reviewed by any firm of independent registered public accountants, such an audit or review process could result in material adjustments to such statement of operations data.

Unaudited Pro Forma Condensed Combined Statement of Operations
Three Months Ended March 31, 2016
(\$ In Millions)

	RCPC Historical	Elizabeth Arden Historical	Pro Forma Adjustments	Notes	Pro Forma Combined
Net Sales	\$ 439.6	\$ 191.9	\$ —		\$ 631.5
Cost of Sales	153.9	107.7	(0.3)	Note 4 (a)	261.3
Gross Profit	285.7	84.2	0.3		370.2
Selling, general, and administrative expenses	245.8	104.1	0.2	Note 4 (c)	350.1
Acquisition and integration costs	0.5	—	—		0.5
Restructuring charges and other, net	1.3	—	—		1.3
Operating income (loss)	<u>\$ 38.1</u>	<u>\$ (19.9)</u>	<u>\$ 0.1</u>		<u>18.3</u>
Other expenses, net:					
Interest expense, net	21.0	6.9	10.6	Note 4 (d)	38.5
Amortization of debt issuance costs	1.5	0.4	(1.1)	Note 4 (d)	0.8
Foreign currency gain, net	(3.4)	—	—		(3.4)
Miscellaneous, net	0.3	—	—		0.3
Other expenses, net	<u>\$ 19.4</u>	<u>\$ 7.3</u>	<u>\$ 9.5</u>		<u>\$ 36.2</u>
Income (loss) from continuing operations before income taxes	18.7	(27.2)	(9.4)		(17.9)
Provision for income taxes	6.1	0.5	(3.3)	Note 4 (e)	3.3
Net income (loss) from continuing operations	<u>\$ 12.6</u>	<u>\$ (27.7)</u>	<u>\$ (6.1)</u>		<u>\$ (21.2)</u>
Income from discontinued operations, net of taxes	0.4	—	—		0.4
Net income attributable to non-controlling interests	—	(0.1)	—		(0.1)
Accretion and dividends on preferred stock	—	(0.6)	0.6	Note 3	—
Net income (loss)	<u><u>\$ 13.0</u></u>	<u><u>\$ (28.4)</u></u>	<u><u>\$ (5.5)</u></u>		<u><u>\$ (20.9)</u></u>

Unaudited Pro Forma Condensed Combined Statement of Operations
Three Months Ended March 31, 2015
(\$ In Millions)

	RCPC Historical	Elizabeth Arden Historical	Pro Forma Adjustments	Notes	Pro Forma Combined
Net Sales	\$ 438.5	\$ 191.7	\$ —		\$ 630.2
Cost of Sales	142.3	112.1	(0.9)	Note 4 (a)	253.5
Gross Profit	296.2	79.6	0.9		376.7
Selling, general, and administrative expenses	246.9	107.1	(0.4)	Note 4 (c)	353.6
Acquisition and integration costs	1.2	—	—		1.2
Restructuring charges and other, net	0.5	—	—		0.5
Operating income	<u>\$ 47.6</u>	<u>\$ (27.5)</u>	<u>\$ 1.3</u>		<u>\$ 21.4</u>
Other expenses, net:					
Interest expense, net	20.0	6.6	10.4	Note 4 (d)	37.0
Amortization of debt issuance costs	1.4	0.4	(1.1)	Note 4 (d)	0.7
Foreign currency loss, net	15.9	—	—		15.9
Other expense, net	<u>\$ 37.3</u>	<u>\$ 7.0</u>	<u>\$ 9.3</u>		<u>\$ 53.6</u>
Income (loss) from continuing operations before income taxes	10.3	(34.5)	(8.0)		(32.2)
Provision for income taxes	9.6	0.5	(2.8)	Note 4 (e)	7.3
Net income (loss) from continuing operations	<u>\$ 0.7</u>	<u>\$ (35.0)</u>	<u>\$ (5.2)</u>		<u>\$ (39.5)</u>
Loss from discontinued operations, net of taxes	(0.1)	—	—		(0.1)
Net loss attributable to non-controlling interests	—	0.5	—		0.5
Accretion and dividends on preferred stock	—	(0.6)	0.6	Note 3	—
Net income (loss)	<u>\$ 0.6</u>	<u>\$ (35.1)</u>	<u>\$ (4.6)</u>		<u>\$ (39.1)</u>

Unaudited Pro Forma Condensed Combined Statement of Operations
Year Ended December 31, 2015
(\$ In Millions)

	RCPC Historical	Elizabeth Arden Historical	Pro Forma Adjustments	Notes	Pro Forma Combined
Net Sales	\$ 1,914.3	\$ 949.2	\$ —		\$ 2,863.5
Cost of Sales	667.8	597.2	(2.6)	Note 4 (a)	1,262.4
Gross Profit	1,246.5	352.0	2.6		1,601.1
Selling, general, and administrative expenses	993.5	482.3	(1.7)	Note 4 (c)	1,474.1
Acquisition and integration costs	8.0	—	—		8.0
Restructuring charges and other, net	10.5	—	—		10.5
Goodwill impairment charge	9.7	—	—		9.7
Operating income (loss)	\$ 224.8	\$ (130.3)	\$ 4.3		\$ 98.8
Other expenses, net:					
Interest expense, net	83.3	27.6	41.0	Note 4 (d)	151.9
Amortization of debt issuance costs	5.7	1.5	(4.2)	Note 4 (d)	3.0
Foreign currency loss, net	15.7	—	—		15.7
Miscellaneous, net	0.4	—	—		0.4
Other expense, net	\$ 105.1	\$ 29.1	\$ 36.8		\$ 171.0
Income (loss) from continuing operations before income taxes	119.7	(159.4)	(32.5)		(72.2)
Provision for income taxes	54.4	6.1	(11.4)	Note 4 (e)	49.1
Net income (loss) from continuing operations	\$ 65.3	\$ (165.5)	\$ (21.1)		\$ (121.3)
Loss from discontinued operations, net of taxes	(3.2)	—	—		(3.2)
Net income attributable to non-controlling interests	—	2.1	—		2.1
Accretion and dividends on preferred stock	—	(2.5)	2.5	Note 3	—
Net income (loss)	\$ 62.1	\$ (165.9)	\$ (18.6)		\$ (122.4)

Unaudited Pro Forma Condensed Combined Balance Sheet
As of March 31, 2016
(\$ In Millions)

	<u>RCPC Historical</u>	<u>Elizabeth Arden Historical</u>	<u>Pro Forma Adjustments</u>	<u>Notes</u>	<u>Pro Forma Combined</u>
ASSETS					
Current Assets:					
Cash and cash equivalents	\$ 182.2	\$ 41.1	\$ (17.9)	Note 4 (d)	\$ 205.4
Trade receivables, net	270.4	123.8	—		394.2
Inventories	209.8	227.5	47.0	Note 4 (a)	484.3
Prepaid expenses and other	68.9	28.1	—		97.0
Receivable from Revlon, Inc.	122.3	—	—		122.3
Total current assets	<u>\$ 853.6</u>	<u>\$ 420.5</u>	<u>\$ 29.1</u>		<u>\$ 1,303.2</u>
Property, plant, and equipment, net	216.6	88.0	20.0	Note 4 (a)	324.6
Deferred income taxes	46.8	3.2	—		50.0
Goodwill	469.7	31.6	(31.6)	Note 4 (a)	735.8
	—	—	266.1	Note 4 (a)	
Intangible assets, net	316.6	227.7	(227.7)	Note 4 (a)	636.1
	—	—	319.5	Note 4 (a),(b)	
Other assets	84.9	22.9	(7.0)	Note 4 (d),(f)	100.8
Total assets	<u>\$ 1,988.2</u>	<u>\$ 793.9</u>	<u>\$ 368.4</u>		<u>\$ 3,150.5</u>
LIABILITIES AND SHAREHOLDERS' (DEFICIENCY) EQUITY					
Current liabilities					
Short-term borrowings	\$ 11.8	\$ 67.5	\$ (67.5)	Note 4 (a)	\$ 11.8
Current portion of long-term debt	6.8	—	11.2	Note 4 (d)	18.0
Accounts payable	178.4	72.0	—		250.4
Accrued expenses and other	225.8	111.4	30.4	Note 4 (d)	364.1
	—	—	(3.5)	Note 4 (a),(d)	
Total current liabilities	<u>\$ 422.8</u>	<u>\$ 250.9</u>	<u>\$ (29.4)</u>		<u>\$ 644.3</u>
Long-term debt	1,783.7	355.0	538.9	Note 4 (a),(d)	2,677.6
Long-term pension and other post-retirement plan liabilities	181.5	—	—		181.5
Other long-term liabilities	73.0	53.6	(36.3)	Note 4 (a),(b)	154.9
			64.6	Note 4 (a),(b)	
Redeemable non-controlling interest	—	2.4	—		2.4
Elizabeth Arden Redeemable Series A Serial Preferred Stock, \$0.01 par value, 50,000 shares authorized:					
50,000 shares issued and outstanding	—	50.0	(50.0)	Note 4 (a)	—
Shareholder's (deficiency) equity:					
RCPC Preferred Stock par value \$1.00 per share; 1,000 shares authorized; 546 issued as of March 31, 2016					
	54.6	—	—		54.6
Elizabeth Arden Common Stock, \$0.01 par value, 50,000,000 shares authorized; 34,790,625 shares issued					
	—	0.4	(0.4)	Note 4 (f)	—
Additional paid-in capital	959.7	380.2	(380.2)	Note 4 (f)	959.7
Accumulated deficit	(1,245.4)	(184.6)	147.2	Note 4 (f)	(1,282.8)
Treasury stock (4,841,308 shares at cost)	—	(93.2)	93.2	Note 4 (f)	—
Non-controlling interest	—	0.3	(0.3)	Note 4 (f)	—
Accumulated other comprehensive loss	(241.7)	(21.1)	21.1	Note 4 (f)	(241.7)
Total stockholders' (deficiency) equity	<u>(472.8)</u>	<u>82.0</u>	<u>(119.4)</u>		<u>(510.2)</u>
Total liabilities and shareholders' deficiency	<u>\$ 1,988.2</u>	<u>\$ 793.9</u>	<u>\$ 368.4</u>		<u>\$ 3,150.5</u>

Note 1: Description of the Transactions

Agreement and Plan of Merger

On June 16, 2016, Products Corporation entered into the Merger Agreement, pursuant to which we have agreed to acquire Elizabeth Arden. At the effective time of the Acquisition, each share of Elizabeth Arden common stock (other than shares held by the Parent, Products Corporation, Acquisition Sub or Elizabeth Arden (including treasury shares) (collectively, the “Excluded Shares”) will be converted into the right to receive \$14.00 in cash, without interest and subject to any applicable withholding taxes (the “Acquisition Consideration”). The Acquisition is subject to customary closing conditions, including approval by Elizabeth Arden shareholders.

As of the effective time of the Acquisition, (i) each stock option of Elizabeth Arden that is outstanding and unexercised immediately before the effective time will be canceled in consideration for the right to receive a cash payment equal to the excess, if any, of the Acquisition Consideration over the exercise price of such stock option; and (ii) each restricted stock unit of Elizabeth Arden will become fully vested and converted into the right to receive an amount in cash equal to the Acquisition Consideration.

Financing

In connection with the Acquisition, Products Corporation will enter into a seven-year \$1,800.0 million New Term Loan Facility and a five-year \$400.0 million New Revolving Credit Facility (together, the “New Senior Facilities”) and \$400 million of senior unsecured financing (the “New Unsecured Financing”). Products Corporation intends to use the net cash proceeds of the New Unsecured Financing and borrowings under the New Term Loan Facility, together with approximately \$100.0 million of borrowings under the New Revolving Credit Facility (subject to changes in working capital requirements and other adjustments) and approximately \$17.9 million of cash on hand to fund the purchase price consideration of the Acquisition, to pay expenses in connection with the Transactions and also to repay, refinance or retire (all amounts outstanding are as of March 31, 2016):

- (i) \$1,311.7 million aggregate principal amount of Product Corporation’s existing (i) 2011 term loan due 2017 and (ii) 2013 term loan due 2019, which are referred to collectively as the “Existing Term Loan”;
- (ii) \$350.0 million aggregate principal amount of Elizabeth Arden’s 7% senior notes due 2021, which are referred to as the “Existing Elizabeth Arden Notes”;
- (iii) \$42.5 million aggregate principal amount of borrowings under Elizabeth Arden’s \$300.0 million revolving credit facility, which is referred to as the “Elizabeth Arden Revolving Facility”;
- (iv) \$25.0 million aggregate principal amount of borrowings under Elizabeth Arden’s second lien credit facility, which is referred to as the “Elizabeth Arden Second Lien Facility”; and
- (v) \$55.0 million liquidation preference of Elizabeth Arden’s Series A Serial Preferred Stock, par value \$0.01 per share, which is referred to as the “Elizabeth Arden Preferred Stock.”

In addition, Products Corporation expects to terminate its existing \$175.0 million amended revolving credit facility due 2018, which is referred to as the “Existing Revolver” and, together with the Existing Term Loan, as the “Existing Senior Facilities.”

The Company also expects to pay Acquisition-related costs of \$30.4 million, as discussed in Note 4(d) below, which would be paid using cash on hand.

The foregoing transactions are referred to as the “Refinancing Transactions,” and the Acquisition and the Refinancing Transactions are referred to as the “Transactions.”

Note 2: Basis of Pro Forma Presentation

The unaudited pro forma condensed combined financial statements are presented to illustrate the effects of the Transactions on the historical financial position and operating results of Products Corporation. The unaudited pro forma condensed combined statements of operations combine the historical consolidated statements of operations of Products Corporation and Elizabeth Arden, giving effect to the Transactions as if they had been

completed on January 1, 2015. The unaudited pro forma condensed combined balance sheet combines the historical consolidated balance sheets of Products Corporation and Elizabeth Arden, giving effect to the Transactions as if they had occurred on March 31, 2016.

Certain reclassifications have been made to the historical financial statements of Elizabeth Arden to conform to the presentation in the consolidated financial statements of Products Corporation. Products Corporation expects there could be additional reclassifications in the year following the completion of the Acquisition, any of which could be material.

The fair values of the net assets acquired are provisional based on management's preliminary estimate of the respective fair values. U.S. GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The process for estimating the fair values of identifiable intangible assets requires the use of significant estimates and assumptions, including estimating future cash flows and developing appropriate discount rates. The excess of the purchase price consideration over the estimated fair value of identifiable assets and liabilities of Elizabeth Arden as of the Acquisition date will be reflected as goodwill. The carrying values of net assets acquired and goodwill are subject to the finalization of Products Corporation's analysis of the fair value of Elizabeth Arden's assets and liabilities as of the Acquisition date and will be adjusted upon completion of the final valuation. The use of different estimates could yield materially different results.

The unaudited pro forma condensed combined financial statements are presented for informational purposes only and are not necessarily indicative of the operating results or financial position of the combined companies that would have occurred if the Transactions had been completed during the period or as of the dates for which the pro forma financial information is presented. In addition, the unaudited pro forma condensed combined financial statements do not purport to project the future consolidated financial position or operating results of the combined companies.

The accompanying unaudited pro forma condensed combined statements of operations do not include: (1) any revenues, synergies or cost reductions that may be achieved subsequent to the completion of the Acquisition; or (2) the impact of non-recurring items directly related to the Transactions.

Note 3: Estimated Purchase Price Consideration

Upon completion of the Acquisition, Products Corporation will acquire Elizabeth Arden for an estimated cash purchase price of \$923.0 million, which Products Corporation will finance from the proceeds of the New Senior Facilities, the New Unsecured Financing and cash on hand. The components of the \$923.0 million estimated purchase price are as follows:

<i>(\$ in millions)</i>	Estimated Purchase Price
Purchase price of Elizabeth Arden common stock ⁽¹⁾	\$ 434.1
Repayment of Existing Elizabeth Arden Notes ⁽²⁾	350.0
Repayment of Elizabeth Arden Revolving Facility ⁽³⁾	42.5
Repayment of Elizabeth Arden Second Lien Facility ⁽³⁾	25.0
Repurchase of Elizabeth Arden Preferred Stock ⁽⁴⁾	55.0
Payment of accrued interest and call premium on Existing Elizabeth Arden Notes ⁽⁵⁾	14.0
Payment of Elizabeth Arden dividends payable at March 31, 2016 ⁽⁶⁾	2.4
Total Purchase Price	\$ 923.0

(1) All of Elizabeth Arden's issued and outstanding common stock will be canceled and extinguished at the effective time of the Acquisition and (other than the Excluded Shares) will be converted into the right to receive \$14.00 in cash, without interest, less any required withholding taxes, which will be paid by Products Corporation upon the completion of the Acquisition. The \$434.1 million estimated purchase price includes the estimated settlement of all outstanding Elizabeth Arden stock options at March 31, 2016 for an estimated cash payment of \$3.9 million and the conversion of all outstanding Elizabeth Arden restricted stock units at March 31, 2016 into the right to receive \$10.9 million of cash at the effective date of the Acquisition.

- (2) The purchase price includes the repurchase of \$350.0 million aggregate principal amount of outstanding Existing Elizabeth Arden Notes.
- (3) The purchase price includes the repayment of \$42.5 million aggregate principal amount outstanding under the \$300.0 million Elizabeth Arden Revolving Facility and \$25.0 million aggregate principal amount outstanding under the Elizabeth Arden Second Lien Facility, respectively, at the effective date of the Acquisition, in each case as of March 31, 2016.
- (4) Per the terms of the Merger Agreement, the purchase price includes \$55.0 million to be paid to retire \$55.0 million liquidation preference of 50,000 shares of Elizabeth Arden Preferred Stock, par value \$0.01 per share.
- (5) Interest on the Existing Elizabeth Arden Notes accrues at a rate of 7.375% per annum and is payable semi-annually on March 15 and September 15 of every year through maturity. The amount of accrued and unpaid interest is calculated based on an assumed 15 days of accrued interest as of March 31, 2016 in the amount of \$1.1 million. Pursuant to the terms of the indenture governing the Existing Elizabeth Arden Notes, upon a change in control, the Existing Elizabeth Arden Notes can be purchased at a price equal to 103.69% of their principal amount, plus accrued and unpaid interest and additional interest, if any, to the date of the repurchase.
- (6) The purchase price includes the payment of approximately \$2.4 million in accrued dividends payable at March 31, 2016 to the holders of Elizabeth Arden Preferred Stock.

Note 4: Pro Forma Adjustments

(a) Preliminary Purchase Price Allocation

For purposes of the preparation of the unaudited pro forma condensed combined financial statements, the fair values of the net assets acquired by Products Corporation in the Acquisition are provisional and are based on management's preliminary estimate of their respective fair values. The process of finalizing the valuation of the net assets acquired may result in material adjustments to the respective fair values and resulting goodwill. As required under applicable accounting guidance, the valuation of the net assets acquired will be finalized no later than one year from the Acquisition date.

The following is a summary of management's preliminary estimate of the fair values of net assets acquired and resulting goodwill in the Acquisition, as reflected in the unaudited pro forma condensed combined balance sheet as of March 31, 2016:

<i>(\$ in millions)</i>	<u>March 31, 2016</u>
Historical equity of Elizabeth Arden	\$ 82.0
Elimination of Elizabeth Arden's historical goodwill	(31.6)
Elimination of Elizabeth Arden's historical intangible assets	(227.7)
Elimination of Existing Elizabeth Arden Notes	355.0
Elimination of Elizabeth Arden Revolving Facility and Elizabeth Arden Second Lien Facility	67.5
Elimination of Elizabeth Arden Preferred Stock	50.0
Accrued dividends payable on Elizabeth Arden Preferred Stock	2.4
Accrued interest on Existing Elizabeth Arden Notes	1.1
Elimination of Elizabeth Arden's historical deferred tax liabilities related to intangible assets	36.3
Fair value adjustment to acquired Elizabeth Arden inventory	47.0
Fair value adjustment to acquired Elizabeth Arden property, plant and equipment	20.0
Fair value of identifiable intangible assets:	
Trade names, indefinite-lived	\$ 135.0
Trade names, finite-lived	14.0
Customer relationships - owned brands	94.0
Customer relationships - licensed and distributed brands	36.0
License agreements	18.0
Distribution rights	20.0
Technology	2.5
Total fair value of identifiable intangible assets	\$ 319.5
Deferred tax impact of purchase accounting adjustments	(64.6)
Residual goodwill resulting from Acquisition	266.1
Total purchase price	<u>\$ 923.0</u>

As discussed in Note 3 above, the purchase price in the Acquisition includes the purchase price of Elizabeth Arden common stock, the repayment of the Existing Elizabeth Arden Notes, amounts outstanding under the Elizabeth Arden Revolving Facility and the Elizabeth Arden Second Lien Facility and the redemption of the Elizabeth Arden Preferred Stock. The preliminary purchase price allocation, as outlined in the table above, has been calculated based upon the carrying values of the Existing Elizabeth Arden Notes, the Elizabeth Arden Revolving Facility, the Elizabeth Arden Second Lien Facility and the Elizabeth Arden Preferred Stock at March 31, 2016.

In determining the fair values of net assets acquired and resulting goodwill, Products Corporation considered, among other factors, analyzes of Elizabeth Arden's historical financial performance and an estimate of the future performance of Elizabeth Arden's business.

The preliminary estimate of the fair values of Elizabeth Arden's indefinite-lived and finite-lived trade names and technology was determined using a risk-adjusted discounted cash flow model under the relief-from-royalty

method. The relief-from-royalty method requires identifying the hypothetical cash flows generated by an assumed royalty rate that a third party would pay to license the trade names or technology, and discounting them back to the valuation date. The royalty rate used was based on a consideration of market rates. The indefinite-lived trade name is *Elizabeth Arden*. The finite-lived trade names include, among others, *Elizabeth Taylor*, *Juicy Couture*, *John Varvatos*, *Britney Spears* and *Wildfox*.

The preliminary estimate of the fair values of Elizabeth Arden's customer relationships and distribution rights was determined using a risk-adjusted discounted cash flow model, specifically, the excess earnings method which considers the use of other assets in the generation of the projected cash flows of a specific asset to isolate the economic benefit generated by the customer relationship and distribution rights assets. The contribution of other assets, such as fixed assets, working capital, workforce, and other intangible assets, to overall cash flows was estimated through contributory asset capital charges. Therefore, the value of Elizabeth Arden's customer relationships and distribution rights assets are the present values of the attributed post-tax cash flows, net of the return on fair value attributed to tangible and other intangible assets.

There are significant judgments inherent in a discounted cash flow valuation approach, including the selection of appropriate discount rates and hypothetical royalty rates and contributory asset capital charges, estimating the amount and timing of estimated future cash flows and identification of appropriate terminal growth rate assumptions. The discount rates used in the discounted cash flow analyzes are intended to reflect the risk inherent in the projected future cash flows to be generated by the respective intangible assets.

The estimated step-up in fair value for Elizabeth Arden's acquired inventory of \$47.0 million was determined based upon the estimated selling price of the inventory less the remaining manufacturing and selling costs and normal profit margin on those manufacturing and selling efforts. Following the Acquisition, the step-up in fair value of \$47.0 million will increase cost of goods sold over approximately five months as the related inventory is sold. This increase in cost of goods sold is not reflected in the unaudited pro forma condensed combined statements of operations because it will not have a recurring impact.

A pro forma adjustment of \$20.0 million was made to increase the carrying value of acquired property, plant and equipment to its estimated fair value of \$108.0 million. The estimated useful lives range from two to six years. The fair value and useful life calculations are preliminary and subject to change after Products Corporation finalizes its review of the specific types, nature, age, condition and location of Elizabeth Arden's property, plant and equipment. Pro forma adjustments for changes in estimated depreciation expense are reflected in the unaudited pro forma condensed combined statements of operations as follows (with respect to cost of goods sold and in Note 4(c) as it relates to selling, general and administrative expenses):

(\$ in millions)	Three Months Ended		Year Ended
	March 31, 2016	March 31, 2015	December 31, 2015
Reversal of Elizabeth Arden's historical depreciation expense	\$ (1.4)	\$ (2.0)	\$ (6.9)
Estimated depreciation expense for acquired Elizabeth Arden property, plant and equipment	1.1	1.1	4.3
Total pro forma adjustments to cost of goods sold	\$ (0.3)	\$ (0.9)	\$ (2.6)

The carrying value of all other assets and liabilities was determined to approximate their fair value.

(b) Acquired Intangible Assets

The acquired intangible assets and related amortization expense is based on Products Corporation's preliminary estimate of the fair values of Elizabeth Arden's identifiable intangible assets, which are as follows:

(\$ in millions)

Acquired Intangible Assets	Fair Value	Estimated Useful Life	For the three months ended		For the year ended
			March 31, 2016	March 31, 2015	December 31, 2015
Trade names, indefinite-lived	\$ 135.0	Indefinite	\$ —	\$ —	\$ —
Trade names, finite-lived	14.0	15	0.2	0.2	0.9
Technology	2.5	10	0.1	0.1	0.3
Customer relationships - owned brands	94.0	16	1.5	1.5	5.9
Customer relationships - licensed and distributed brands	36.0	16	0.6	0.6	2.3
License agreements	18.0	20	0.2	0.2	0.9
Distribution rights	20.0	16	0.3	0.3	1.2
Total acquired intangible assets	\$ 319.5				
Total amortization expense			\$ 2.9	\$ 2.9	\$ 11.5

Deferred Tax Liability

A non-current deferred tax liability of \$64.6 million was recorded against the \$319.5 million estimated fair value of Elizabeth Arden's acquired intangible assets outlined in the above table. The deferred tax liabilities represent the tax effect of the difference between the estimated assigned fair value of the finite-lived intangible assets (\$184.5 million) and the tax basis (\$0) of such assets. The estimated amount of \$64.6 million was determined by multiplying the difference of \$184.5 million by Products Corporation's statutory federal income tax rate of 35.0%.

The unaudited pro forma condensed combined balance sheet as of March 31, 2016 also includes a pro forma adjustment of (\$36.3 million) to deferred income taxes-noncurrent within long-term liabilities to eliminate Elizabeth Arden's deferred tax liability on its historical intangible assets.

(c) Selling, General and Administrative Expenses

Pro forma adjustments made to SG&A expense within the unaudited pro forma condensed combined statements of operations consist of the following:

(\$ in millions)	Three Months Ended		Year Ended
	March 31, 2016	March 31, 2015	December 31, 2015
Reversal of Elizabeth Arden's amortization expense on historical intangible assets	\$ (3.0)	\$ (3.0)	\$ (11.9)
Amortization expense for acquired intangible assets shown in (b) above	2.9	2.9	11.5
Reversal of Elizabeth Arden's historical depreciation expense	(5.9)	(6.5)	(26.1)
Estimated depreciation expense for acquired property, plant and equipment	6.2	6.2	24.8
Total pro forma adjustments to SG&A	\$ 0.2	\$ (0.4)	\$ (1.7)

(d) Financing transactions

Upon the effective date of the Acquisition, Products Corporation will use the net cash proceeds from borrowings under the New Term Loan Facility, the New Revolving Credit Facility and the New Unsecured Financing, as well as cash on hand, to fund the purchase price of the Acquisition and to refinance certain existing indebtedness of Elizabeth Arden and Products Corporation, as described in Note 1, "Description of the Transactions."

Use of Proceeds

The use of proceeds from the New Term Loan Facility, the New Revolving Credit Facility, the New Unsecured Financing and cash on hand to be used in the Transactions is reflected in the unaudited pro forma condensed combined balance sheet as of March 31, 2016 as follows:

<i>(\$ in millions)</i>	March 31, 2016
New Term Loan Facility, 7-year maturity	\$ 1,800.0
New Revolving Credit Facility, 5-year maturity	100.0
New Unsecured Financing	400.0
Debt Discounts ⁽¹⁾	(68.1)
Total Proceeds from New Senior Facilities and New Unsecured Financing	\$ 2,231.9
Refinance Products Corporation's Existing Term Loan ⁽²⁾	(1,311.7)
Purchase Price, including refinance of Elizabeth Arden indebtedness	(923.0)
Debt Issuance Costs, presented as a deduction from the face value of related debt ^{(3) (4)}	(15.1)
Acquisition-related costs ⁽⁵⁾	—
Total pro forma adjustment to cash and cash equivalents	\$ (17.9)

- (1) Debt discounts of approximately \$54.1 million and \$14.0 million, for the purposes of pro forma presentation, represent amounts to be paid to the lenders. At the effective date of the Acquisition, these amounts will be accounted for as a reduction from the proceeds received as a component of the premium or discount at issuance and will be amortized over the terms of the New Term Loan Facility and the New Unsecured Financing, respectively. See "Interest Expense" below for the pro forma adjustments.
- (2) Products Corporation's Existing Term Loan consists of: (i) the 2011 Term Loan, which is due in November 2017, with an aggregate outstanding principal amount of \$651.4 million as of March 31, 2016; and (ii) the 2013 Term Loan, which is due October 2019, with an aggregate outstanding principal amount of \$660.3 million as of March 31, 2016.
- (3) Products Corporation expects to incur debt issuance costs of approximately \$15.1 million as of the Acquisition date, which are recorded as a deduction from the face value of the long-term debt pro forma adjustment in the unaudited pro forma condensed combined balance sheet as of March 31, 2016. The debt issuance costs will be amortized over the life of the New Senior Facilities and the New Unsecured Financing. See "Interest Expense and Debt Issuance Costs" below for the pro forma adjustment.
- (4) Products Corporation also made a pro forma adjustment to eliminate Elizabeth Arden's capitalized financing fees of \$7.0 million as of March 31, 2016 in the unaudited pro forma condensed combined balance sheet.
- (5) Of the anticipated Acquisition-related costs to be incurred by Products Corporation, \$30.4 million were unpaid, and no such costs were recorded by Products Corporation during the three months ended March 31, 2016. The total acquisition-related costs of \$30.4 million are assumed to be accrued as of March 31, 2016, and are included as a pro forma adjustment to accumulated deficit and accrued expenses and other in the unaudited pro forma condensed combined balance sheet as of March 31, 2016.

The current and long-term portions of debt and pro forma adjustments to accrued expenses related to borrowings under the New Senior Facilities and the incurrence of the New Unsecured Financing in the unaudited pro forma condensed combined balance sheet as of March 31, 2016 are summarized as follows:

<i>(\$ in millions)</i>	<u>March 31, 2016</u>
Current portion of long-term debt	
Products Corporation historical current portion long-term debt at March 31, 2016	\$ 6.8
Current portion of borrowings under the existing Products Corporation facilities ⁽¹⁾	18.0
Elimination of Products Corporation's historical current portion of long-term debt	<u>(6.8)</u>
Pro forma adjustment to current portion of long-term debt	11.2
Total pro forma current portion of long-term debt	<u>\$ 18.0</u>

(1) Current portion calculated as 1% amortization on \$1.8 billion of New Term Loan Facility.

<i>(\$ in millions)</i>	<u>March 31, 2016</u>
Long-term debt	
Products Corporation historical long-term debt at March 31, 2016	\$ 1,783.7
Existing Elizabeth Arden Notes, including \$5.0 million premium	355.0
Total Proceeds from the New Senior Facilities and the New Unsecured Financing	2,231.9
Refinance Products Corporation's Existing Term Loan	(1,311.7)
Elimination of Existing Elizabeth Arden Notes, including \$5.0 million premium	(355.0)
Debt Issuance Costs, presented as a deduction from the face value of related debt	<u>(15.1)</u>
Total pro forma adjustment to total debt	\$ 550.1
Less: Pro forma adjustment to current portion of long-term debt (see above)	<u>(11.2)</u>
Pro forma adjustment to long-term debt	538.9
Total pro forma long-term debt	<u>\$ 2,677.6</u>

<i>(\$ in millions)</i>	<u>March 31, 2016</u>
Accrued dividends payable and accrued interest included in purchase price	
Elimination of accrued dividends payable on Elizabeth Arden Preferred Stock	\$ (2.4)
Elimination of Elizabeth Arden accrued interest on the Existing Elizabeth Arden Notes	<u>(1.1)</u>
Pro forma adjustment to accrued expenses and other	<u>\$ (3.5)</u>

Interest Expense and debt issuance costs

Pro forma interest expense and debt issuance costs resulting from the New Senior Facilities and the New Unsecured Financing are as follows:

<i>(\$ in millions)</i>	<u>Three Months Ended</u>		<u>Year Ended</u>
	<u>March 31, 2016</u>	<u>March 31, 2015</u>	<u>December 31, 2015</u>
Interest Expense			
Pro forma interest on New Senior Facilities and New Unsecured Financing	\$ 30.0	\$ 29.7	\$ 119.5
Reversal of Elizabeth Arden's historical interest expense ⁽¹⁾	(6.9)	(6.6)	(27.6)
RCPC historical interest expense related to Existing Term Loan, as reflected in the historical consolidated financial statements	<u>(12.5)</u>	<u>(12.7)</u>	<u>(50.9)</u>
Total Adjustment for Pro Forma Interest Expense	\$ 10.6	\$ 10.4	\$ 41.0
Debt issuance costs			
Amortization of debt issuance costs	\$ 0.6	\$ 0.6	\$ 2.4
RCPC historical amortization of debt issuance costs related to Existing Term Loan Facility, as reflected in the historical consolidated financial statements	(1.3)	(1.3)	(5.1)
Reversal of Elizabeth Arden's historical amortization of debt issuance costs	<u>(0.4)</u>	<u>(0.4)</u>	<u>(1.5)</u>
Total Adjustment for Pro Forma Amortization of Debt Issuance Costs	\$ (1.1)	\$ (1.1)	\$ (4.2)

- (1) As discussed in Note 4(a), the purchase price includes the repayment of \$350.0 million aggregate principal amount of Existing Elizabeth Arden Notes, as well as an aggregate of \$67.5 million of borrowings outstanding under the Elizabeth Arden Revolving Facility and the Elizabeth Arden Second Lien Facility. At March 31, 2016, Elizabeth Arden had \$42.5 million and \$25.0 million in borrowings outstanding under the Elizabeth Arden Revolving Facility and the Elizabeth Arden Second Lien Facility, respectively. Elizabeth Arden's historical interest expense was reversed as pro forma adjustments in the unaudited pro forma condensed combined statements of operations.

(e) Provision for Income Taxes

The pro forma adjustment to the provision for income taxes was calculated using the statutory federal income tax rate of 35.0%, as detailed below:

(\$ in millions)	Three Months Ended		Year Ended
	March 31, 2016	March 31, 2015	December 31, 2015
Cost of Goods Sold			
Adjustment	\$ (0.3)	\$ (0.9)	\$ (2.6)
Tax expense	0.1	0.3	0.9
Interest Expense and Debt Issuance Costs			
Adjustment	9.5	9.3	36.8
Tax benefit	(3.3)	(3.3)	(12.9)
SG&A Expenses			
Adjustment	0.2	(0.4)	(1.7)
Tax (benefit) expense	(0.1)	0.2	0.6
Total Adjustment for Pro Forma Tax Benefit	<u>\$ (3.3)</u>	<u>\$ (2.8)</u>	<u>\$ (11.4)</u>

(f) Equity

As shown in the purchase price allocation in Note 4(a) above, Elizabeth Arden's historical equity is eliminated in the unaudited pro forma condensed combined balance sheet as of March 31, 2016. As discussed in Note 4(d) above, a pro forma adjustment of \$30.4 million and \$7.0 million was made to accumulated deficit for Transaction-related costs that had not been incurred as of March 31, 2016 and historical debt issuance as of March 31, 2016, respectively. Pro forma accumulated deficit as a result of the Transactions is summarized below:

	March 31, 2016
Products Corporation historical accumulated deficit at March 31, 2016	\$ (1,245.4)
Elizabeth Arden historical accumulated deficit at March 31, 2016	(184.6)
Elimination of historical Elizabeth Arden accumulated deficit	184.6
Pro forma adjustment for Transaction-related costs	(30.4)
Elimination of historical Elizabeth Arden debt issuance costs	(7.0)
Pro forma adjustment to accumulated deficit	\$ 147.2
Total pro forma accumulated deficit	<u>\$ (1,282.8)</u>

RECONCILIATIONS OF NON-GAAP FINANCIAL INFORMATION

The non-GAAP financial information and related reconciliations set forth below were provided to prospective investors in connection with the Acquisition.

Use of Non-GAAP Financial Information

Revlon Consumer Products Corporation

We present Adjusted EBITDA (as defined below) and Pro Forma Adjusted EBITDA (as defined below) (collectively, the “EBITDA-Based Measures”). Our EBITDA-Based Measures are non-GAAP financial measures that are reconciled to their most directly comparable GAAP measure, net income (loss).

Adjusted EBITDA is defined as net income (loss) before income (loss) from discontinued operations (net of taxes), income from continuing operations (net of taxes), interest expense, taxes, depreciation and amortization, amortization of debt issuance, gains (losses) on foreign currency (losses) gains, gains (losses) on the early extinguishment of debt and miscellaneous expenses, including certain additional adjustments. In calculating Adjusted EBITDA, we also exclude the effects of various items that our management believes are not directly attributable to our operating performance, such as non-cash stock compensation expense, restructuring and related charges, acquisition and integration costs, gains and accruals relating to a fire in Venezuela, shareholder litigations recoveries (charges), inventory purchase accounting adjustments, pension settlement charges, deferred consideration in connection with acquisitions and charges in connection with executive management changes. We also exclude the effects of various items our management believes are unusual, such as Adjusted EBITDA from our Venezuela operations, an inventory obsolescence reserve and gains on the sale of certain non-core brands. Management believes that excluding such non-operating and unusual items improves comparability of our EBITDA-Based Measures from period to period because some of these items are not tied to our operations, may not occur in certain periods or can vary significantly from period to period in a manner that may not facilitate an understanding of our ongoing operating performance.

Pro Forma Adjusted EBITDA is Adjusted EBITDA calculated on a pro forma basis, including (i) adjustments relating to the Transactions that are permitted to be made in connection with an acquisition of a business under Article 11 of Regulation S-X, and (ii) additional adjustments, such as net cost reductions and synergies that we believe in good faith can be achieved in connection with the Transactions but that are not permitted to be made in connection with an acquisition of a business under Article 11 of Regulation S-X. As a result, Pro Forma Adjusted EBITDA may not be comparable with other pro forma financial measures calculated entirely in accordance with Article 11 of Regulation S-X.

Our management utilizes our EBITDA-Based Measures as operating performance measures (in conjunction with GAAP and other non-GAAP financial measures) as integral parts of our reporting and planning processes and as one of the primary measures to, among other things, (i) monitor and evaluate the performance of our business operations; (ii) facilitate management’s internal comparisons of our historical operating performance of our business operations; (iii) facilitate management’s external comparisons of the results of our overall business to the historical operating performance of other companies that may have different capital structures and debt levels; (iv) review and assess the operating performance of our management team and, together with other operational objectives, as a measure in evaluating employee compensation and bonuses; (v) analyze and evaluate financial and strategic planning decisions regarding future operating investments; and (vi) plan for and prepare future annual operating budgets and determine appropriate levels of operating investments. Our management believes that our EBITDA-Based Measures are useful to investors to provide them with disclosures of our operating results on the same basis as that used by our management. Additionally, our management believes that our EBITDA-Based Measures provide useful information to investors about the performance of our overall business because such measures eliminate the effects of unusual or other infrequent charges that are not directly attributable to our underlying operating performance. Additionally, our management believes that providing these non-GAAP measures enhances the comparability for investors in assessing our financial reporting. Accordingly, we believe that our EBITDA-Based Measures, when used in conjunction with GAAP financial measures, are useful financial analytical tools, used by our management as described above, that can assist investors in assessing our financial condition, operating performance and underlying strength. Our EBITDA-Based Measures should not be considered in isolation or as a substitute for their respective most directly comparable as reported financial measures prepared in accordance with GAAP, such as net income/loss or net cash provided by (used in) operating activities. Other companies may define such non-GAAP financial measures differently. The calculation of our EBITDA-Based Measures may also differ from the calculation of “Consolidated EBITDA” (or similar financial measures) for purposes of the indenture or the agreements governing our other indebtedness.

Our presentation of our EBITDA-Based Measures should not be construed as an indication that our future results will be unaffected by unusual or non-recurring items. Our EBITDA-Based Measures have limitations as analytical tools and you should not consider them in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:

- the EBITDA-Based Measures do not reflect every cash expenditure, future requirements for capital expenditures or contractual commitments;
- they do not reflect the significant interest expense or the cash requirements necessary to service interest or principal payments on our debt;
- with respect to our EBITDA-Based Measures, although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced or require improvements in the future, and they do not reflect any cash requirements for such replacements or improvements;
- our EBITDA-Based Measures are not adjusted for all non-cash income or expense items that are reflected in our statements of cash flows;
- our EBITDA-Based Measures do not reflect the impact of earnings or charges resulting from matters we consider not to be indicative of our ongoing operations;
- they do not reflect limitations on our ability to transfer earnings or cash from our subsidiaries to Products Corporation;
- Pro Forma Adjusted EBITDA reflects certain adjustments that are not permitted under Article 11 of Regulation S-X, such as the expected cost reductions and synergies, which may not be achieved; and
- other companies in our industry may calculate these financial measures differently than we do, limiting their usefulness as comparative measures.

Because of these limitations, our EBITDA-Based Measures should not be considered as a measure of discretionary cash available to us to invest in the growth of our business or as a measure of cash that will be available to us to meet our obligations, including those under the notes. We compensate for these limitations by using our EBITDA-Based Measures, along with other comparative tools, including GAAP financial measures, to assist in the evaluation of our operating performance. Such GAAP measures include operating income (loss), net income (loss), cash flows from operations and cash flow data.

Our EBITDA-Based Measures are not intended as alternatives to net income (loss) as an indicator of our operating performance, as alternatives to any other measure of performance in conformity with GAAP or as alternatives to cash flow provided by (used in) operating activities as measures of liquidity. You should therefore not place undue reliance on our EBITDA-Based Measures or ratios calculated using such measures. Our GAAP-based financial measures can be found in our consolidated financial statements and the related notes thereto as filed with the SEC.

Elizabeth Arden's EBITDA ("Elizabeth Arden EBITDA") and Elizabeth Arden's Adjusted EBITDA ("Elizabeth Arden Adjusted EBITDA") are non-GAAP measures; Elizabeth Arden Adjusted EBITDA is defined as net income (loss) attributable to Elizabeth Arden common shareholders plus (i) the provision for income taxes (or net loss less the benefit from income taxes or plus the provision for income taxes), (ii) interest expense, (iii) depreciation and amortization expense, (iv) net income (loss) attributable to noncontrolling interest, (v) accretion and dividends on preferred stock and (vi) depreciation related to cost of goods sold. Elizabeth Arden EBITDA should not be considered as an alternative to income (loss) from operations or net income (loss) attributable to Elizabeth Arden common shareholders (as determined in accordance with GAAP) as a financial measure of Elizabeth Arden's operating performance, or to net cash provided by (used in) operating, investing or financing activities (as determined in accordance with GAAP) or as a measure of Elizabeth Arden's ability to meet cash needs. Elizabeth Arden Adjusted EBITDA is defined as Elizabeth Arden EBITDA plus non-recurring and other costs. Elizabeth Arden believes that Elizabeth Arden EBITDA and Elizabeth Arden Adjusted EBITDA are financial measures commonly reported and widely used by investors and other interested parties as a measure of a company's operating performance and debt servicing ability because they assist in comparing performance on a consistent basis without regard to capital structure, depreciation and amortization, preferred stock accretion or dividends or non-operating factors (such as historical cost). Accordingly, as a result of Elizabeth Arden's capital structure, Elizabeth Arden believes Elizabeth Arden EBITDA and Elizabeth Arden Adjusted EBITDA are relevant financial measures. This information has been disclosed to permit a more complete comparative analysis of Elizabeth Arden's operating performance relative to other companies and of Elizabeth Arden's debt servicing ability. Elizabeth Arden EBITDA and Elizabeth Arden Adjusted EBITDA may not, however, be comparable in all instances to other similar types of financial measures.

In addition, Elizabeth Arden EBITDA and Elizabeth Arden Adjusted EBITDA have limitations as analytical tools, including the fact that:

- they do not reflect Elizabeth Arden's cash expenditures, future requirements for capital expenditures or contractual commitments;
- they do not reflect the significant interest expense or the cash requirements necessary to service interest or principal payments on Elizabeth Arden's debt or dividends or redemption value of Elizabeth Arden's preferred stock;
- they do not reflect any cash income taxes that Elizabeth Arden may be required to pay; and
- although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future and these measures do not reflect any cash requirements for such replacements.

Elizabeth Arden EBITDA should be read in conjunction with Elizabeth Arden's consolidated financial statements and the related footnotes thereto as filed with the SEC.

The following table reconciles our EBITDA, Adjusted EBITDA and Pro Forma Adjusted EBITDA to the most comparable U.S. GAAP financial measure, our net income.

(USD millions)	Full Year					LTM	Q1	Q1
	2011	2012	2013	2014	2015	March 2016	March 2016	March 2015
Net Income	\$64.0	\$71.2	\$1.6	\$47.3	\$62.1	\$74.5	\$13.0	\$0.6
Interest Expense	91.1	85.3	78.6	84.4	83.3	84.3	21.0	20.0
Loss (income) from Discontinued Operations	1.8	10.1	30.4	(1.3)	3.2	2.7	(0.4)	0.1
Amortization of Debt Issuance Costs	3.7	3.4	3.5	5.5	5.7	5.8	1.5	1.4
Foreign Currency Losses (Gains), Net	4.7	2.8	3.7	25.0	15.7	(3.6)	(3.4)	15.9
Loss on Early Extinguishment of Debt	11.2	0.0	29.7	2.0	0.0	0.0	0.0	0.0
Miscellaneous, Net	1.6	1.2	1.0	1.2	0.4	0.7	0.3	0.0
Provision for Income Taxes	35.4	44.8	48.6	81.2	54.4	50.9	6.1	9.6
Depreciation and Amortization	60.6	64.9	76.7	102.6	103.2	103.5	25.9	25.6
EBITDA	\$274.1	\$283.7	\$273.8	\$347.9	\$328.0	\$318.8	\$64.0	\$73.2
EBITDA	\$274.1	\$283.7	\$273.8	\$347.9	\$328.0	\$318.8	\$64.0	\$73.2
<i>Add back certain non-operating items:</i>								
Non-cash stock compensation expense	\$1.9	\$0.3	\$0.2	\$5.5	\$5.1	\$5.7	\$2.2	\$1.6
Restructuring and related charges	--	24.1	4.5	22.6	11.6	12.2	1.3	0.7
Acquisition and integration costs	--	--	25.4	6.4	8.0	7.4	0.5	1.2
Inventory purchase accounting adjustments	--	--	8.5	2.6	0.9	0.9	--	--
Pension lump sum settlement accounting	--	--	--	--	20.7	20.7	--	--
Non-cash impairment charge	--	--	--	--	9.7	9.7	--	--
Deferred consideration for CBB Acquisition	--	--	--	--	2.5	3.4	0.9	--
Insurance gain related to the 2011 fire in Venezuela	--	--	(26.4)	--	--	--	--	--
Accrual for Venezuela fire clean-up	--	--	7.6	--	--	--	--	--
<i>Add back certain unusual items:</i>								
Venezuela Adjusted EBITDA	--	--	--	(6.6)	--	--	--	--
Inventory obsolescence reserve	--	--	--	(3.4)	--	--	--	--
Gain on sale of certain non-core professional brands	--	--	--	--	(3.0)	--	--	(3.0)
Executive management changes	--	--	--	--	--	0.9	0.9	--
Adjusted EBITDA, excluding certain non-operating and unusual items	\$276.0	\$308.1	\$293.6	\$375.0	\$383.5	\$379.6	\$69.8	\$73.7
Elizabeth Arden Adjusted EBITDA, excluding certain non-operating and unusual items					(\$2.1)(1)	\$6.4 (2)	(\$7.2)(3)	(\$15.7)(3)
Acquisition Synergies				139.3		139.3		
RCPC Pro Forma Adjusted EBITDA, excluding certain non-operating and unusual items				\$520.7		\$525.3	\$62.6	\$58.0
Revlon, Inc. General and Administrative Expenses	(7.4)	(10.4)	(9.9)	(9.8)	(9.0)	(8.9)	(2.3)	(2.4)
Revlon, Inc. Pro Forma Adjusted EBITDA, excluding certain non-operating and unusual items	\$268.6	\$297.7	\$283.7	\$365.2	\$511.7	\$516.4	\$60.3	\$55.6
Pro Forma Adjusted Net Sales								
Net Sales - Revlon						\$1,915.4		
Net Sales - EA						949.4		
Elizabeth Arden Net Sales Adjustments						13.3		
Pro Forma Adjusted Net Sales						\$2,878.1		

(1) Elizabeth Arden Adjusted EBITDA is a non-GAAP financial measure. For more information regarding Elizabeth Arden Adjusted EBITDA, see "Use of Non-GAAP Financial Measures--Elizabeth Arden" in this Exhibit 99.2. Elizabeth Arden Adjusted EBITDA for the twelve months ended December 31, 2015 consists of the arithmetic sum of (x) Elizabeth Arden Adjusted EBITDA for the fiscal year ended June 30, 2015 plus (y) Elizabeth Arden Adjusted EBITDA for the six months ended December 31, 2015 minus (y) Elizabeth Arden Adjusted EBITDA for the six months ended December 31, 2014. Results for such twelve-month period are not necessarily indicative of the results that would be achieved during a fiscal year. For a reconciliation of Elizabeth Arden Adjusted EBITDA to the most comparable U.S. GAAP measure, net income, (x) for the year ended June 30, 2015, see Elizabeth Arden's current report on Form 8-K, furnished on August 6, 2015, (y) for the six months ended December 31, 2015 and December 31, 2014, see Elizabeth Arden's current report on Form 8-K, furnished on February 4, 2016.

(2) Elizabeth Arden Adjusted EBITDA for the twelve months ended March 31, 2016 consists of the arithmetic sum of (x) Elizabeth Arden Adjusted EBITDA for the fiscal year ended June 30, 2015 plus (y) Elizabeth Arden Adjusted EBITDA for the nine months ended March 31, 2016 minus (y) Elizabeth Arden Adjusted EBITDA for the nine months ended March 31, 2015. Results for such twelve-month period are not necessarily indicative of the results that would be achieved during a fiscal year. For a reconciliation of Elizabeth Arden Adjusted EBITDA to the most comparable U.S. GAAP measure, net income, (x) for the year ended June 30, 2015, see Elizabeth Arden's current report on Form 8-K, furnished on August 6, 2015, (y) for the nine

months ended March 31, 2016 and March 31, 2015, see Elizabeth Arden's current report on Form 8-K, furnished on May 5, 2016.

- (3) For a reconciliation of Elizabeth Arden Adjusted EBITDA to the most comparable U.S. GAAP measure, net income for the three months ended March 31, 2016 and March 31, 2015, see Elizabeth Arden's current report on Form 8-K, furnished on May 5, 2016.